European Commission logo
English English
CORDIS - EU research results
CORDIS

A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Project description

Experimental vaccine for the treatment of Chordoma and head and neck cancer

The head and neck group of cancers includes diseases involving the head and neck, including mouth, throat and salivary glands, with 650 000 new cases annually. Chordoma is a rare cancer of the skull base and the spine. Currently, there are no approved drugs for chordoma treatment. Biotech company MaxiVAX developed a cancer vaccine comprising an immune boost agent released in situ by an engineered cell line and cancer autologous cells providing antigens. A Phase I trial with 25 patients with an advanced stage of cancer showed encouraging efficacy data and safety profile of the treatment. The current EU-funded MaxONCO project Phase II clinical trial will evaluate this vaccine in 45 patients with head and neck cancer and in chordoma patients. The chordoma trial will be conducted in the EU and USA as an Investigational New Drug programme that allows fast-track marketing of the drug in case of successful trial results.

Objective

MaxiVAX a private Swiss clinical-stage biotech company with a novel cancer immunotherapy product in development (MaxONCO) will perform Phase 2 clinical trial in Head & Neck indication and prepare the commercialization of MaxONCO, its first immuno-therapy product. The objective of the Phase II clinical trial is to demonstrate efficacy and safety of MaxONCO in the patients treated and compare the results to the current standard of care.
MaxONCO is a biological product acting as a cancer vaccine and composed of (i) an immune boost agent released in
situ by a genetically modified cell line and (ii) cancer autologous cells, which are the source of antigens. A Phase 1
trial in 25 patients with a range of cancer types at an advanced stage showed encouraging efficacy data and a benign
safety profile of the treatment.
Head and Neck cancer is a group of cancers that develops in the areas of the head and neck which include the mouth,
throat and salivary glands; accounting for 650,000 new cases in 2018 diagnosed globally. With the approval of
Swissmedic, MaxiVAX has initiated the Phase 2 clinical trial to evaluate MaxONCO in 40-45 patients with Head
& Neck cancer. The study will be conducted across 4-6 different sites in Switzerland. Encouraging clinical results
show that among 4 initial Head & Neck patients treated with MaxONCO all survived beyond the 6-month time point
(primary efficacy end point).
Currently accounting for 8 employees, the company plans to grow up to 25 employees by the end of the SME phase
2 project, creating up to 30 indirect jobs.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Coordinator

MAXIVAX SA
Net EU contribution
€ 2 785 300,00
Address
Avenue de Sécheron 15
1202 Geneva
Switzerland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Schweiz/Suisse/Svizzera Région lémanique Genève
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 979 000,00